IGF-1:Tetanus toxin fragment C fusion protein improves delivery of IGF-1 to spinal cord but fails to prolong survival of ALS mice

Brain Research

Volumn 1287, Issue , 2009, Pages 1-19

  Chian, Ru Ju ^a   Li, Jianhong ^a   Ay, Ilknur ^a   Celia, Samuel A ^a   Kashi, Brenda B ^a   Tamrazian, Eric ^a   Matthews, Jonathan C ^a   Bronson, Roderick T ^b   Rossomando, Anthony ^c   Pepinsky, R Blake ^c   Fishman, Paul S ^d,e   Brown Jr , Robert H ^a   Francis, Jonathan W ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER HARVARD CANCER CENTER   (United States)

^c BIOGEN   (United States)

^d BALTIMORE VA MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Amyotrophic lateral sclerosis; Drug delivery; Fusion protein; IGF 1; Motor neuron; SOD1G93A transgenic mice; Tetanus toxin fragment C

Indexed keywords

BRAIN ENZYME; GANGLIOSIDE GT 1B; HYBRID PROTEIN; INSULIN LIKE GROWTH FACTOR TETANUS TOXIN FRAGMENT C FUSION PROTEIN; PROTEIN KINASE B; RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TETANUS TOXIN; UNCLASSIFIED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; LUMBAR SPINAL CORD; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RETROGRADE NERVE FIBER TRANSPORT; SPINAL CORD; SPINAL CORD MOTONEURON; SURVIVAL; THERAPY EFFECT; TRANSGENIC MOUSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BACULOVIRIDAE; CELLS, CULTURED; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC VECTORS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SPINAL; INSULIN-LIKE GROWTH FACTOR I; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR NEURONS; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; SPINAL CORD; SPODOPTERA; TETANUS TOXIN;

ANIMALIA; HEXAPODA; MUS; MUS MUSCULUS;

EID: 68049090807     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.06.066     Document Type: Article

References (65)

1. Ahmad S., Singh N., and Glazer R.I. Role of AKT1 in 17beta-estradiol and insulin-like growth factor I (IGF-1)-dependent proliferation and prevention of apoptosis in MCF-7 breast carcinoma cells. Biochem. Pharmacol. 58 (1999) 425-430
2. Alexi T., Hughes P., van Roon-Mom W., Faull R., Williams C., Clark R., and Gluckman P. The IGF-1 amino-terminal tripeptide glycine-proline-glutamate is neuroprotective in striatum on the quinolinic acid lesion model of Huntington's disease. Exp. Neurol. 159 (1999) 84-97
3. Baneyx F., and Mujacic M. Recombinant protein folding and misfolding in Escherichia coli. Nat. Biotechnol. 22 (2004) 1399-1408
4. Benn S.C., Ay I., Bastia E., Chian R., Celia S.A., Pepinsky R.B., Fishman P.S., Brown R.H., and Francis J.W. Tetanus toxin fragment C fusion facilitates protein delivery to CNS neurons from cerebrospinal fluid in mice. J. Neurochem. 95 (2005) 1118-1131
5. Bizzini B., Stoeckel K., and Schwab M. An antigenic polypeptide fragment isolated from tetanus toxin: chemical characterization, binding to gangliosides, and retrograde axonal transport in various neuron systems. J. Neurochem. 28 (1977) 529-542
6. Borasio G.D., Robberecht W., Leigh P.N., et al. A placebo-controlled trial of insulin-like growth factor-1 in amyotrophic lateral sclerosis. Neurology 51 (1998) 583-586
7. Bordet T., Castelnau-Ptakhine L., Fauchereau F., Friocourt G., Kahn A., and Haase G. Neuronal targeting of cardiotrophin-1 by coupling with tetanus toxin C fragment. Mol. Cell. Neurosci. 17 (2001) 842-854
8. Buell G., Schulz M., Selzer G., Chollet A., Movva N., Semon D., Escanez S., and Kawashima E. Optimizing the expression in E. coli of a synthetic gene encoding somatomedin-C (IGF-1). Nucleic Acids Res. 13 (1987) 1923-1938
9. Butler W.B., Kelsey W.H., and Goran N. Effects of serum and insulin on the sensitivity of the human breast cancer line MCF-7 to estrogen and anti-estrogens. Cancer Res. 41 (1981) 82-88
10. Cabot J.B., Mennone A., Bogan N., Carroll J., Evinger C., and Erichsen J.T. Retrograde, trans-synaptic, and transneuronal transport of fragment C of tetanus toxin by sympathetic preganglionic neurons. Neurosci 40 (1991) 805-823
11. Caroni P., and Grandes P. Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factors. J. Cell. Biol. 110 (1990) 1307-1317
12. Carro E., Trejo J., Gerber A., Loetscher H., Torrado J., Metzger F., and Torres-Aleman I. Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol. Aging 27 (2006) 1250-1257
13. Charles I.G., Rodgers B.C., Makoff A.J., Chatfield S.N., Slater D.E., and Fairweather N.F. Synthesis of tetanus toxin fragment C in insect cells by use of a baculovirus expression system. Infect. Immun. 59 (1991) 1627-1632
14. Coen L., Osta R., Maury M., and Brulet P. Construction of hybrid proteins that migrate retrogradely and transynaptically in the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 9400-9405
15. Contreras P.C., Steffler C., Yu E., Callison K., and Stong D. Recombinant human IGF-1, Des(1-3)IGF-1, and R3IGF-1 enhance functional recovery from sciatic nerve crush in mice. Ann. N.Y. Acad. Sci. 692 (1993) 314-316
16. Dobrenis K., Joseph A., and Rattazzi M. Neuronal lysosomal enzyme replacement using fragment C of tetanus toxin. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 2297-2301
17. Dobrowolny G., Giacinti C., Pelosi L., Nicoletti C., Winn N., Barberi L., Molinaro M., Rosenthal N., and Musaro A. Muscle expression of a local IGF-1 isoform protects motor neurons in an ALS mouse model. J. Cell. Biol. 168 (2005) 193-199
18. Dodge J., Haidet A., Yang W., Passini M., Hester M., Clarke J., Roskelley E., Treleaven C., Rizo L., Martin H., Kim S., Kaspar R., Taksir T., Griffiths D., Cheng S., LS S., and Kaspar B. Delivery of AAV-IGF-1 to the CNS extends survival in ALS mice through modification of aberrant glial cell activity. Mol. Ther. 16 (2008) 1056-1064
19. Elliott S., Fagin K., Narhi L., Miller J., Jones M., Koski R., Peters M., Hsieh P., Sachdev R., Rosenfeld R., Rohde M., and Arakava T. Yeast-derived recombinant human insulin-like growth factor 1: production, purification and structural characterization. J. Protein Chem. 9 (1990) 95-104
20. Evinger C., and Erichsen J.T. Transsynaptic retrograde transport of fragment C of tetanus toxin demonstrated by immunohistochemical localization. Brain Res. 380 (1986) 383-388
21. Fishman P.S., and Carrigan D.R. Retrograde transneuronal transfer of the C-fragment of tetanus toxin. Brain Res. 406 (1987) 275-279
22. Fishman P.S., and Carrigan D.R. Motoneuron uptake from the circulation of the binding fragment of tetanus toxin. Arch. Neurol. 45 (1988) 558-561
23. Forsberg G., Palm G., Ekebacke A., Josephson S., and Hartmanis M. Separation and characterization of modified variants of recombinant human insulin-like growth factor 1 derived from a fusion protein secreted from Escherichia coli. Biochem. J. 271 (1990) 357-363
24. Francis J., Brown Jr. R.H., Figueiredo D., Remington M., Castillo O., Schwarzschild M., Fishman P., Murphy J., and vanderSpek J. Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons. J. Neurochem. 74 (2000) 2528-2536
25. Franz C., Federici T., Yang J., Backus C., Oh S., Teng Q., Carlton E., Bishop K., Gasmi M., Bartus R., Feldman E., and Boulis N. Intraspinal cord delivery of IGF-1 mediated by adeno-associated virus 2 is neuroprotective in a rat model of familial ALS. Neurobiol. Disease 33 (2009) 473-481
26. Guan J., Welliams C., Gunning M., Mallard C., and Gluckman P. The effects of IGF-1 treatment after hypoxic-ischemic brain injury in adult rats. J. Cereb. Blood Flow Metab. 13 (1993) 609-616
27. Gurney M.E., Pu H., Chiu A.Y., Dal Canto M.C., Polchow C.Y., Alexander D.D., Caliendo J., Hentati A., Kwon Y.W., Deng H.-X., Chen W., Zhai P., Sufit R.L., and Siddique T. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264 (1994) 1772-1775
28. Halpern J.A., and Loftus A. Characterization of the receptor-binding domain of tetanus toxin. J. Biol. Chem. 268 (1993) 11188-11192
29. Halpern J.L., Habig W.H., Neale E.A., and Stibitz S. Cloning and expression of functional fragment C of tetanus toxin. Infect. Immun. 58 (1990) 1004-1009
30. Halpern J.L., and Neale E.A. Neurospecific binding, internalization, and retrograde transport. Curr. Topics Microbiol. Immunol. 195 (1995) 221-241
31. Hantai D., Akaaboune M., Lagord C., Murawsky M., Houenou L.J., Festoff B.W., Vaught J.L., Rieger F., and Blondet B. Beneficial effects of insulin-like growth factor-1 on wobbler mouse motoneuron disease. J. Neurol. Sci. 129 Suppl. (1995) 122-126
32. Heiman-Patterson T., Deitch J., Blankenhorn E., Erwin K., Perreault M., Alexander B., Byers N., Toman I., and Alexander G. Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 236 (2005) 1-7
33. Helting T.B., and Zwisler O. Enzymatic breakdown of tetanus toxin. Biochem. Biophys. Res. Comm. 57 (1974) 1263-1270
34. Herreros J., Lalli G., Montecucco C., and Schiavo G. Tetanus toxin fragment C binds to a protein present in neuronal cell lines and motorneurons. J. Neurochem. 74 (2000) 1941-1950
35. Herreros J., Lalli G., and Schiavo G. C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor. Biochem. J. 347 (2000) 199-204
36. Iwasaki Y., and Ikeda K. Prevention by insulin-like growth factor-1 and riluzol in motor neuron death after neonatal axotomy. J. Neurol. Sci. 169 (1999) 148-155
37. Johnston L., Wawas F., Tierney R., Qazi O., Fairweather N., and Sesardic D. Transcutaneous delivery of tetanus toxin Hc fragment induces superior tetanus toxin neutralizing antibody response compared to tetanus toxoid. Hum. Vaccin. 5 (2009) 1-7
38. Kaspar B.K., Llado J., Sherkat N., Rothstein J.D., and Gage F.H. Retrograde viral delivery of IGF-1 prolongs survival in mouse ALS model. Science 301 (2003) 839-842
39. Lai E., Felice K., Festoff B., et al. Effect of recombinant human insulin-like growth factor-1 on progression of ALS: a placebo-controlled study. Neurology 49 (1997) 1621-1630
40. Larsen K., Benn S., Ay I., Chian R.-J., Celia S., Remington M., Bejarano M., Liu M., Ross J., Carmillo P., Sah D., Phillips K., Sulzer D., Fishman P., Pepinsky R., Brown Jr. R., and Francis J. A glial cell line-derived neurotrophic factor (GDNF):tetanus toxin fragment C protein conjugate improves delivery of GDNF to spinal cord motor neurons in mice. Brain Res. 1120 (2006) 1-12
41. G93A model of ALS. Brain Res. 1185 (2007) 256-265
42. Makoff A.J., Oxer M.D., Romanos M.A., Fairweather N.F., and Ballantine S. Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons. Nucleic. Acids. Res. 17 (1989) 10191-10202
43. Messi M., Clark H., Prevette D., Oppenheim R., and Delbono O. The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS. Exp. Neurol. 207 (2007) 52-63
44. Nagano I., Ilieva H., Shiote M., Murakami T., Yokoyama M., Shoji M., and Abe K. Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J. Neurol. Sci. 235 (2005) 61-68
45. Nagaraja T., Patel P., Gorski M., Gorevic P., Patlak C., and Fenstermacher J. In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with limited distribution into brain. Cerebrospinal. Fluid Res. 2 (2005) 1-15
46. G93A transgenic mice. J. Neurosci. Res. 82 (2005) 452-457
47. Payne A.M., Zheng Z., Messi M.L., Milligan C.E., Gonzalez E., and Delbono O. Motor neurone targeting of IGF-1 prevents specific force decline in ageing mouse muscle. J. Physiol. 570 (2006) 283-294
48. Peters M., Lau E., Snitman D., Van Wyk J., Underwood L., Riussell W., and Svoboda M. Expression of a biologically active analog of somatomedin-C/insulin-like growth factor-1. Gene 35 (1985) 83-89
49. C fragment of tetanus toxin forms stable, concentration-dependent dimers via an intermolecular disulfide bond. J. Mol. Biol. 365 (2007) 123-134
50. Qazi O., Sesardic D., Tierney R., Soderback Z., Crane D., Bolgiano B., and Fairweather N. Reduction of the ganglioside binding activity of the tetanus toxin Hc fragment destroys immunogenicity: implications for development of novel tetanus vaccines. Infect. Immun. 74 (2006) 4884-4891
51. Rinderknecht E., and Humbel R. The amino acid sequence of human insulin-like growth factor 1 and its structural homology with proinsulin. J. Biol. Chem. 253 (1978) 2769-2776
52. Rogers T.B., and Snyder S.H. High affinity binding of tetanus toxin to mammalian cell membranes. J. Biol. Chem. 256 (1981) 2402-2407
53. Romanelli R., LeBeau A., Fulmer C., Lazzarino D., Hochber A., and Wood T. Insulin-like growth factor-1 receptor internalization and recycling mediate the sustained phosphorylation of Akt. J. Biol. Chem. 282 (2007) 22513-22524
54. Salmon Jr. W., and Daughaday W. A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. J. Lab. Clin. Med. 49 (1957) 825-836
55. Samuelsson E., Wadensten H., Hartmanis M., Moks T., and Uhlen M. Facilitated in vitro refolding of human recombinant insulin-like growth factor 1 using a solubilizing fusion partner. BioTechnology 9 (1991) 363-366
56. Schwab M.E., Suda K., and Thoenen H. Selective retrograde transsynaptic transfer of a protein, tetanus toxin, subsequent to its retrograde axonal transport. J. Cell Biol. 82 (1979) 798-810
57. Sharma H. Neuroprotective effects of neurotrophins and melanocortins in spinal cord injury: an experimental study in the rat using pharmacological and morphological approaches. Ann. N.Y. Acad. Sci. 1053 (2005) 407-421
58. c fragment: ganglioside binding, cell binding, and retrograde axonal transport properties. Mol. Microbiol. 37 (2000) 1041-1051
59. Sorenson E., Windbank A., Mandrekar J., Bamlet W., Appel S., Armon C., Barkhaus P., Bosch P., Boylan K., David W., Feldman E., et al. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology 71 (2008) 1770-1775
60. Soule H.D., Vazguez J., Long A., Albert S., and Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 51 (1973) 1409-1416
61. Stewart A.J., Johnson M.D., May F.E.B., and Westley B.R. Role of insulin-like growth factors and the type 1 insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 265 (1990) 21172-21178
62. Thoenen H., and Sendtner M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. 5 (2002) 1046-1050
63. van Heyningen W.E. Gangliosides as membrane receptors for tetanus toxin, cholera toxin, and serotonin. Nature 249 (1974) 415-417
64. Weller U., Taylor C.F., and Habermann E. Quantitative comparison between tetanus toxin, some fragments, and toxoid for binding and axonal transport in the rat. Toxicon 24 (1986) 1055-1063
65. Wu W., Xu X., and Hao J. Chronic lumbar catheterization of the spinal subarachnoid space in mice. J. Neurosci. Methods 133 (2004) 65-69